Covid-19 Action Plan – 2021 Update
In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and our wider community from the Covid-19
In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and our wider community from the Covid-19
Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication. Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping
The outbreak of the novel viral disease, COVID-19, caused by the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has led to worldwide health and economic catastrophe.1 Almost 2 million cases and
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in place to ensure